GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Total Liabilities

ReNeuron Group (LSE:RENE) Total Liabilities : £4.00 Mil (As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Total Liabilities?

ReNeuron Group's Total Liabilities for the quarter that ended in Sep. 2023 was £4.00 Mil.

ReNeuron Group's quarterly Total Liabilities declined from Sep. 2022 (£6.75 Mil) to Mar. 2023 (£4.59 Mil) and declined from Mar. 2023 (£4.59 Mil) to Sep. 2023 (£4.00 Mil).

ReNeuron Group's annual Total Liabilities increased from Mar. 2021 (£6.45 Mil) to Mar. 2022 (£7.44 Mil) but then declined from Mar. 2022 (£7.44 Mil) to Mar. 2023 (£4.59 Mil).


ReNeuron Group Total Liabilities Historical Data

The historical data trend for ReNeuron Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Total Liabilities Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.27 7.15 6.45 7.44 4.59

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.28 7.44 6.75 4.59 4.00

ReNeuron Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ReNeuron Group's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.32+(0.268+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=4.59

Total Liabilities=Total Assets (A: Mar. 2023 )-Total Equity (A: Mar. 2023 )
=9.645-5.057
=4.59

ReNeuron Group's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.813+(0.189+-3.885780586188E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=4.00

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=6.423-2.421
=4.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ReNeuron Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.